GoldenGolden
Advanced Search
ARCH Venture Partners

ARCH Venture Partners

A venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease.

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Timeline

1986
Founded

Invested in

Associated investment funds

Patents

Products

Funding Rounds Participated In

People

Name
Role
LinkedIn

Amber Lu

Employee

Joshua White

Advisor

Keith Gillard

Board member

Michael Knapp

Employee

Mike Slawson

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Epirium Bio

EQRx

Omniome

Sonoma BioTherapeutics

Transcenta

News

Title
Author
Date
Publisher
Description
March 31, 2021
Eudora Wang
March 4, 2021
DealStreetAsia
eGenesis was created in 2015 by George Church and Yang, who also launched China's Qihan Biotech in 2017.
Allison DeAngelis
March 3, 2021
Business Insider
Biotech investor Arch Venture Partners and tech investor General Catalyst have teamed up on a SPAC focused on mental health and/or virtual health.
Allison DeAngelis
February 2, 2021
Business Insider
Arch Venture Partners has raised a $1.85 billion fund. It plans to invest in mental health and manufacturing startups, as well as drug companies.
Nick Paul
January 29, 2021
FierceBiotech
Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.